Imazodan is primarily used in the field of cardiovascular research due to its role as a selective phosphodiesterase III inhibitor. It is studied for its potential to enhance cardiac function by increasing cyclic AMP levels, which leads to improved myocardial contractility and vasodilation. This makes it a compound of interest in the development of treatments for heart failure and other cardiac conditions. Additionally, its mechanism of action is explored in pharmacological studies to understand its effects on smooth muscle relaxation and its potential applications in managing pulmonary hypertension. Imazodan's properties are also investigated in preclinical settings to evaluate its efficacy and safety profile for therapeutic use.